SCHEMBL4720050

SCHEMBL4720050

Fc1ccccc1C1CNCc2cc(OCCCN3CCCCC3)ncc21

nearest known ligand 0.79

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 19/20 0.79
SLC6A4 P31645 18/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4721213 0.89 HRH3 (1.00) HRH3SLC6A4
SCHEMBL4721189 0.87 SLC6A4 (1.00) HRH3SLC6A4
SCHEMBL4723197 0.85 SLC6A4 (0.82) HRH3SLC6A4
SCHEMBL4720479 0.85 SLC6A4 (0.81) HRH3SLC6A4
SCHEMBL4722939 0.83 SLC6A4 (0.85) HRH3SLC6A4
SCHEMBL4720198 0.83 SLC6A4 (1.00) HRH3SLC6A4
SCHEMBL4722736 0.82 SLC6A4 (1.00) HRH3SLC6A4
SCHEMBL4721192 0.81 HRH3 (0.81) HRH3SLC6A4
SCHEMBL4719851 0.80 SLC6A4 (1.00) HRH3SLC6A4
SCHEMBL4722875 0.80 SLC6A4 (1.00) HRH3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899334-B1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP claimed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US claimed
EP-1899334-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP claimed
WO-2006138714-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO claimed
US-20060287292-A1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 US claimed
EP-1899334-B1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
EP-1899334-B1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US disclosed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US disclosed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US disclosed
EP-1899334-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
WO-2006138714-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO disclosed
US-20060287292-A1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287292-A1 NAPHTHYRIDINE COMPOUNDS HRH3, HRH4, HRH1 HRH3 1/4885SLC6A4 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.